Protective effect of Korean red ginseng on oxaliplatin-mediated splenomegaly in colon cancer
Annals of Surgical Treatment and Research
;
: 161-167, 2018.
Artigo
em Inglês
| WPRIM
| ID: wpr-716855
ABSTRACT
PURPOSE:
This study investigated how adding Korean red ginseng extract (KRG) to folinic acid, fluorouracil and oxaliplatin (FOLFOX) chemotherapy affected the rate of splenomegaly in colon cancer.METHODS:
This retrospective study analyzed 42 patients who were randomly assigned to receive a FOLFOX regimen with or without KRG. Spleen volume change was assessed by computed tomography scans measured before surgery (presurgery volume) and 3 weeks after cessation of the 12th cycle of FOLFOX (postchemotherapy volume).RESULTS:
All patients showed increased spleen volume. No difference was observed in median presurgery and postchemotherapy volume between the KRG and control groups. However, a ratio defined as postchemotherapy volume divided by presurgery volume was significantly lower in the KRG group than the control group (median, 1.38 [range, 1.0–2.8] in KRG group vs. median, 1.89 [range, 1.1–3.0] in control group, P = 0.028). When splenomegaly was defined as a >61% increase in spleen volume, the rate of splenomegaly was significantly lower in the KRG group than the control group (28.6% vs. 61.9%, P = 0.03). KRG consumption was inversely associated with developing splenomegaly in multivariate analysis.CONCLUSION:
Adding KRG during FOLFOX chemotherapy for colon cancer might protect against oxaliplatin-induced splenomegaly. The protective effect of Korean red ginseng should be investigated with further research.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Baço
/
Esplenomegalia
/
Leucovorina
/
Análise Multivariada
/
Estudos Retrospectivos
/
Colo
/
Neoplasias do Colo
/
Tratamento Farmacológico
/
Fluoruracila
/
Panax
Tipo de estudo:
Estudo observacional
Limite:
Humanos
Idioma:
Inglês
Revista:
Annals of Surgical Treatment and Research
Ano de publicação:
2018
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS